Christopher Liu
Stock Analyst at LUCID CAPITAL MARKETS
(2.96)
# 1,356
Out of 5,241 analysts
11
Total ratings
87.5%
Success rate
43.53%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Christopher Liu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NXTC NextCure | Initiates: Buy | $25 | $9.74 | +156.67% | 1 | May 11, 2026 | |
| RLMD Relmada Therapeutics | Initiates: Buy | $14 | $6.90 | +102.90% | 1 | Mar 2, 2026 | |
| EXEL Exelixis | Upgrades: Outperform | $48 | $50.13 | -4.25% | 2 | Oct 21, 2025 | |
| LYEL Lyell Immunopharma | Initiates: Buy | $20 | $17.92 | +11.61% | 1 | Sep 26, 2025 | |
| ADAG Adagene | Initiates: Buy | $9 | $3.50 | +157.14% | 1 | Sep 18, 2025 | |
| GNLX Genelux | Initiates: Buy | $10 | $2.92 | +242.47% | 1 | Jul 21, 2025 | |
| RLAY Relay Therapeutics | Maintains: Outperform | $19 → $18 | $12.20 | +47.54% | 1 | Dec 4, 2024 | |
| IDYA IDEAYA Biosciences | Downgrades: Market Perform | $41 → $27 | $28.21 | -4.29% | 2 | Nov 5, 2024 | |
| NUVL Nuvalent | Initiates: Market Perform | $42 | $102.30 | -58.94% | 1 | Aug 8, 2023 |
NextCure
May 11, 2026
Initiates: Buy
Price Target: $25
Current: $9.74
Upside: +156.67%
Relmada Therapeutics
Mar 2, 2026
Initiates: Buy
Price Target: $14
Current: $6.90
Upside: +102.90%
Exelixis
Oct 21, 2025
Upgrades: Outperform
Price Target: $48
Current: $50.13
Upside: -4.25%
Lyell Immunopharma
Sep 26, 2025
Initiates: Buy
Price Target: $20
Current: $17.92
Upside: +11.61%
Adagene
Sep 18, 2025
Initiates: Buy
Price Target: $9
Current: $3.50
Upside: +157.14%
Genelux
Jul 21, 2025
Initiates: Buy
Price Target: $10
Current: $2.92
Upside: +242.47%
Relay Therapeutics
Dec 4, 2024
Maintains: Outperform
Price Target: $19 → $18
Current: $12.20
Upside: +47.54%
IDEAYA Biosciences
Nov 5, 2024
Downgrades: Market Perform
Price Target: $41 → $27
Current: $28.21
Upside: -4.29%
Nuvalent
Aug 8, 2023
Initiates: Market Perform
Price Target: $42
Current: $102.30
Upside: -58.94%